Fundraising Fox
Sangamo Therapeutics
Unknown based on the provided page content, US · Founded 1995 · 229 employees on LinkedIn · 4 known investors
Find your way into Sangamo Therapeutics
Sign up to see every warm intro you have to Sangamo Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Sangamo Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Sangamo Therapeutics develops gene-editing therapeutics using zinc finger and modular integrase platforms to treat genetic diseases including hemophilia, Fabry disease, and neuropathy. The company is currently undergoing Chapter 11 reorganization and conducting clinical trials for various therapeutic applications.
Founders & leadership
SM
Sandy MacraeChief Executive OfficerSandy Macrae is President and CEO of Sangamo Therapeutics, a company developing gene-editing and genomic medicine therapeutics for genetic diseases including hemophilia and Fabry disease.
Investors · 4
Frequently asked questions
- What does Sangamo Therapeutics do?
- Sangamo Therapeutics develops gene-editing therapeutics using zinc finger and modular integrase platforms to treat genetic diseases including hemophilia, Fabry disease, and neuropathy. The company is currently undergoing Chapter 11 reorganization and conducting clinical trials for various therapeutic applications.
- Who are Sangamo Therapeutics's investors?
- Sangamo Therapeutics's investors include California Technology Ventures, Foothill Ventures, Foresite Capital, Ridgeback Capital.
- Where is Sangamo Therapeutics headquartered?
- Sangamo Therapeutics is headquartered in Unknown based on the provided page content, US.